1/2
06:00 am
exas
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
Low
Report
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
12/13
11:16 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Bank of America Co. from $75.00 to $72.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Bank of America Co. from $75.00 to $72.00. They now have a "buy" rating on the stock.
12/12
07:32 am
exas
Bladder Cancer Detection Kit Market to Hit USD 2.99 Billion by 2032, Driven by Advancements in Non-Invasive Technologies | Research by SNS Insider [Yahoo! Finance]
Low
Report
Bladder Cancer Detection Kit Market to Hit USD 2.99 Billion by 2032, Driven by Advancements in Non-Invasive Technologies | Research by SNS Insider [Yahoo! Finance]
12/9
10:06 am
exas
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates [Yahoo! Finance]
Low
Report
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates [Yahoo! Finance]
12/5
09:25 am
exas
Exploring High Growth Tech Stocks in December 2024 [Yahoo! Finance]
Low
Report
Exploring High Growth Tech Stocks in December 2024 [Yahoo! Finance]
12/2
09:42 am
exas
Exact Sciences and Lil Jon Partner on "Get Low #2" Campaign to Encourage Colon Cancer Screening [Yahoo! Finance]
Low
Report
Exact Sciences and Lil Jon Partner on "Get Low #2" Campaign to Encourage Colon Cancer Screening [Yahoo! Finance]
11/26
12:52 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at TD Cowen from $82.00 to $86.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at TD Cowen from $82.00 to $86.00. They now have a "buy" rating on the stock.
11/26
12:29 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at BTIG Research from $65.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at BTIG Research from $65.00 to $75.00. They now have a "buy" rating on the stock.
11/26
12:27 pm
exas
Why Is Exact Sciences Stock Trading Higher On Monday? [Yahoo! Finance]
Low
Report
Why Is Exact Sciences Stock Trading Higher On Monday? [Yahoo! Finance]
11/26
06:00 am
exas
Exact Sciences to Participate in December Investor Conferences
Low
Report
Exact Sciences to Participate in December Investor Conferences
11/25
05:41 pm
exas
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024 [Yahoo! Finance]
Low
Report
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024 [Yahoo! Finance]
11/25
05:35 pm
exas
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
Low
Report
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
11/21
09:53 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its "outperform" rating re-affirmed by analysts at William Blair.
11/19
07:02 pm
exas
Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
11/19
04:11 pm
exas
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]
Low
Report
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]
11/18
08:35 am
exas
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test [Yahoo! Finance]
Low
Report
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test [Yahoo! Finance]
11/18
08:12 am
exas
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community [Yahoo! Finance]
Low
Report
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community [Yahoo! Finance]
11/18
04:37 am
exas
Cancer Profiling Market Research Report 2024 - Global Forecasts to 2029: Biomarker-Based Tumor Profiling and Point-of-Care Innovations Driving Growth [Yahoo! Finance]
Low
Report
Cancer Profiling Market Research Report 2024 - Global Forecasts to 2029: Biomarker-Based Tumor Profiling and Point-of-Care Innovations Driving Growth [Yahoo! Finance]
11/16
07:42 am
exas
Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock [Yahoo! Finance]
Low
Report
Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock [Yahoo! Finance]
11/13
04:12 pm
exas
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]
Low
Report
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]
11/13
01:00 pm
exas
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Low
Report
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
11/11
08:09 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.
11/6
02:11 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.
11/6
02:10 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.
11/6
01:10 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $95.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $95.00 to $75.00. They now have a "buy" rating on the stock.